In conclusion, in breast cancer, any new clinical trial testing bortezomib should compare bortezomib in combination (e.g., trastuzumab) vs the single molecule, and should include patients with proteasome high activity, which could be indirectly evaluated by UBE2C IHC staining. Here, UBE2C is linked to breast carcinoma.